The study of propranolol treatment for hemangioma of infancy- A hospital based observational study

Authors

  • Masuda Khatun Associate professor, Department of Dermatology and Venereology, Dhaka Medical College.
  • MM Abu Sayed Senior Consultant, National Institute of Cancer Research and Hospital.
  • Monira Pervin Associate Professor, Departent of Virology, Dhaka Medical College

DOI:

https://doi.org/10.3329/jpsb.v7i1.69551

Keywords:

propranolol treatment, hemangioma

Abstract

Background: Infantile haemangiomas are the most common tumours of infancy, regularly encountered in dermatology and paediatric practices.

Methods: One hundred patients from Dhaka Medical College Hospital were treated with oral propranolol for IHs between May 2015 and December 2015.

Results: Majority 25(69.45%) patients belonged to age ≤6 months, the mean age was found 4.2±5.0 months. Males were predominant (80.6%). Male female ratio was 4.14:1. Regarding facial segments 10(27.8%) patients had S3. Two (6.0%) patients had trunk lesions. Eyelid was found 6(17.0%). Ulcerated hemangioma was found in 4(12.0%). Mean severity scores were significantly reduces from 4 to 32 weeks when compare with baseline and different follow up.

Conclusion: Majority hemangioma patients belonged to age ≤6 months, mean severity scores were significantly reduced from 4 to 32 weeks when compared with baseline and different follow up.

Journal of Paediatric Surgeons of Bangladesh (2016) Vol. 7 (1): 11-14

Downloads

Download data is not yet available.
Abstract
2
PDF
2

Downloads

Published

2018-04-12

How to Cite

Khatun, . M. ., Sayed, M. A. ., & Pervin, M. . (2018). The study of propranolol treatment for hemangioma of infancy- A hospital based observational study. Journal of Paediatric Surgeons of Bangladesh, 7(1), 11–14. https://doi.org/10.3329/jpsb.v7i1.69551

Issue

Vol. 7 No. 1 (2016)

Section

Original Articles

License

Authors of articles published in JPSB retain the copyright of their articles and are free to reproduce and disseminate their work. A Copyright and License Agreement – signed and dated by the corresponding author on behalf of all authors – must be submitted with each manuscript submission.